All SAMatrix™ Technology products serve as a primary layer for acute and chronic wounds to conform to the wound bed¹, allow cellular growth,^2† and resorb³ while providing sustained antimicrobial protection on the matrix^4,5† and — with the PainGuard^® line extension — reducing topical pain⁶.

No. Because of the highly conformal nature of SAMatrix™, it is able to reach the micro-contours of the wound bed and is 99.99% effective on the matrix across a wide range of common wound pathogens,^4,5† while having a very low level of silver — 0.16mg/in² (2.5 mg/100 cm²)^6,7.

Yes. SAMatrix™ has been demonstrated in vitro to be effective against a wide range of microorganisms, including Candida albicans, Methicillin Resistant Staphylococcus aureus (MRSA), Vancomycin Resistant Enterococcus (VRE), Pseudomonas aeruginosa, Klebsiella pneumoniae, Staphylococcus aureus, Escherichia coli, and Candida tropicalis. SAMatrix™ delivers sustained antimicrobial action for at least 72 hours on the matrix.^4,5†

Yes, however, SAMatrix™ is not indicated to treat infected wounds. Please note that it is not contraindicated for use on infected or at-risk wounds and is indicated for use on all wounds.⁶ Physicians should follow proper wound bed debridement prior to application and administer systemic antibiotics when indicated.

Yes, SAMatrix™ products are biocompatible⁸, non-pyrogenic⁹, and have FDA clearance to manage surgically-created wounds⁶, with no contraindications related to closure techniques.

The ultrathin form factor of SAMatrix™ is a key design element of the product. It allows SAMatrix™ to conform to the wound bed¹ and brings the matrix functionality to the “nooks and crannies” of the wound. Comparatively, bulky macro-scale matrices and traditional antimicrobial wound dressings sit well above the wound bed and force the granulation cells to come to them.

Yes. Clinically, SAMatrix™ can be used from day 1 on a freshly debrided wound to help manage bioburden and support a wound healing environment. These products can be integrated into the protocol of care for that wound type and used in conjunction with other wound management technologies and solutions. Important to note: if application is occurring in an outpatient care setting where separate product reimbursement may be possible, please refer to and confirm payer policy guidelines. 

We recommend that a dry wound be moistened with sterile saline after routine debridement and prior to application of SAMatrix™. A non-adherent gauze and light pressure to the matrix can also be applied to achieve maximum conformity to the wound bed and its edges.

Yes, in clinical cases, SAMatrix™ has been demonstrated compatible with wound VAC/NPWT, although it has not been formally studied for safety and effectiveness.

SAMatrix™ should be covered with a non-adherent dressing and any other dressings needed to maintain a moist wound environment. Change the cover dressing as needed to maintain a moist wound environment or whenever SAMatrix™ is reapplied.

Reapply SAMatrix™ depending on the wound and the healing progression, or when clinically indicated. To reapply, carefully remove the cover dressing(s). Gently irrigate wound with sterile saline to remove necrotic tissue. It is not necessary to remove any residual SAMatrix™ — including the PainGuard™ version — observed during cover dressing changes.

Yes, they may overlap without concern. Regarding PainGuard^® matrices, please follow the dosing guidance charts to determine (by body weight) the maximum number of pieces that can be safely applied within a 24-hour period.

Yes, there is a limit that becomes a clinical consideration at low body weights and/or larger-sized pieces of SAMatrix™ matrix. The patient cannot exceed the maximum 24-hour lidocaine dose of 4.5 mg/kg.

Color differences within the matrix may occur and are expected because of slight variations in the size of metallic silver particles. However, this does not impact product performance.

Yes. SAMatrix™ products should be cut to size slightly larger than the wound. Multiple pieces may be used to cover the wound bed and the wound margin.

Do not use on individuals who are sensitive to silver, lidocaine, or any local anesthetics of the amide type, or who have had a prior allergic reaction to SAMatrix™ or any of its components.

Prior to use, please refer to the full Instructions for Use (IFU) for complete prescribing information. Avoid concomitant use with iodophor-containing products, which may reduce the antimicrobial effectiveness of silver in the dressing. For SAMatrix™ with PainGuard™, avoid contact with the eyes.

SAMatrix™ products without lidocaine have a shelf life of 4 years. SAMatrix™ with PainGuard^® products have a shelf life of 2 years.

Microlyte^® and Microlyte^® PainGuard^® have been assigned HCPCS Level II codes A2005 and A2040, respectively, by CMS. These codes support product identification for billing purposes. Coverage and reimbursement are determined by individual payers and are subject to applicable policies, contracts, and patient-specific circumstances.